PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26172393-4	2015	Furthermore, CK2alpha and CK2alpha", catalytic subunits of CK2, were observed to translocate into nuclear in cancer cells with the treatment of DOX.	Doxorubicin	144-147	casein kinase 2 alpha 2	Homo sapiens	13-21	
34359939-0	2021	CK2alpha/CSNK2A1 Induces Resistance to Doxorubicin through SIRT6-Mediated Activation of the DNA Damage Repair Pathway.	Doxorubicin	39-50	casein kinase 2 alpha 2	Homo sapiens	0-8	
31713447-9	2019	Further results demonstrated that CK2alpha could interact with YBX1 and PI3K/AKT antagonist decreased cell resistance to doxorubicin induced by co-activation of CK2alpha and YBX1.	Doxorubicin	121-132	casein kinase 2 alpha 2	Homo sapiens	34-42	
31713447-9	2019	Further results demonstrated that CK2alpha could interact with YBX1 and PI3K/AKT antagonist decreased cell resistance to doxorubicin induced by co-activation of CK2alpha and YBX1.	Doxorubicin	121-132	casein kinase 2 alpha 2	Homo sapiens	161-169	
26172393-4	2015	Furthermore, CK2alpha and CK2alpha", catalytic subunits of CK2, were observed to translocate into nuclear in cancer cells with the treatment of DOX.	Doxorubicin	144-147	casein kinase 2 alpha 2	Homo sapiens	26-34	
22695718-3	2012	Knockdown of CK2alpha in MCF7-derived cells expressing MRP1 [MRP1 CK2alpha(-)] resulted in increased doxorubicin sensitivity.	Doxorubicin	101-112	casein kinase 2 alpha 2	Homo sapiens	13-21	
22695718-3	2012	Knockdown of CK2alpha in MCF7-derived cells expressing MRP1 [MRP1 CK2alpha(-)] resulted in increased doxorubicin sensitivity.	Doxorubicin	101-112	casein kinase 2 alpha 2	Homo sapiens	66-74	
22695718-6	2012	Studies in tissue culture confirmed these findings, showing increased intracellular doxorubicin accumulation in MRP1 CK2alpha(-) and MRP1-T249A cells compared with MRP1 cells.	Doxorubicin	84-95	casein kinase 2 alpha 2	Homo sapiens	117-125